Hyperfine (HYPR) Capital Expenditures (QoQ) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Hyperfine | 149.47 Mn | 108.20 Mn | 1.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.69% |
| Dec 31, 2025 | 132.10% |
| Sep 30, 2025 | 80.85% |
| Jun 30, 2025 | -183.10% |
| Mar 31, 2025 | 235.73% |
| Dec 31, 2024 | -335.85% |
| Sep 30, 2024 | 130.23% |
| Jun 30, 2024 | -170.89% |
| Mar 31, 2024 | 187.60% |
| Dec 31, 2023 | -50.19% |
| Sep 30, 2023 | 6,575.00% |
| Jun 30, 2023 | -122.22% |
| Mar 31, 2023 | -77.22% |
| Dec 31, 2022 | -8.67% |
| Sep 30, 2022 | 420.37% |
| Jun 30, 2022 | -117.53% |
| Mar 31, 2022 | -68.41% |
| Dec 31, 2021 | -8.11% |
| Sep 30, 2021 | 110.10% |
| Jun 30, 2021 | 197.06% |